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Prorenin Accumulation and Activation in
Human Endothelial Cells
Importance of Mannose 6-Phosphate Receptors
Mark M.E.D. van den Eijnden, Jasper J. Saris, René J.A. de Bruin, Elly de Wit, Wim Sluiter,
Timothy L. Reudelhuber, Maarten A.D.H. Schalekamp, Frans H.M. Derkx, A.H. Jan Danser
Abstract—ACE inhibitors improve endothelial dysfunction, possibly by blocking endothelial angiotensin production.
Prorenin, through its binding and activation by endothelial mannose 6-phosphate (M6P) receptors, may contribute to this
production. Here, we investigated this possibility as well as prorenin activation kinetics, the nature of the
prorenin-activating enzyme, and M6P receptor–independent prorenin binding. Human umbilical vein endothelial cells
(HUVECs) were incubated with wild-type prorenin, K/A-2 prorenin (in which Lys42 is mutated to Ala, thereby
preventing cleavage by known proteases), M6P-free prorenin, and nonglycosylated prorenin, with or without M6P,
protease inhibitors, or angiotensinogen. HUVECs bound only M6P-containing prorenin (Kd 0.960.1 nmol/L, maximum
number of binding sites [Bmax] 1010650 receptors/cell). At 37°C, because of M6P receptor recycling, the amount of
prorenin internalized via M6P receptors was .25 times Bmax. Inside the cells, wild-type and K/A-2 prorenin were
proteolytically activated to renin. Renin was subsequently degraded. Protease inhibitors interfered with the latter but not
with prorenin activation, thereby indicating that the activating enzyme is different from any of the known
prorenin-activating enzymes. Incubation with angiotensinogen did not lead to endothelial angiotensin generation,
inasmuch as HUVECs were unable to internalize angiotensinogen. Most likely, therefore, in the absence of
angiotensinogen synthesis or endocytosis, M6P receptor–mediated prorenin internalization by endothelial cells
represents prorenin clearance. (Arterioscler Thromb Vasc Biol. 2001;21:911-916.)
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Vascular angiotensin II (Ang II), through stimulation ofAng II type 1 (AT1) receptors, induces the generation
of superoxide anions, thereby resulting in endothelial
dysfunction.1 Blockade of this process, with ACE inhibi-
tors or AT1 receptor antagonists, reverses endothelial
dysfunction in human atherosclerosis.2 At present, it is still
being debated whether vascular Ang II generation depends
on locally synthesized or circulating kidney-derived renin.
In support of the latter, angiotensins cannot be demon-
strated in the perfusate of vascular preparations obtained
from nephrectomized animals, unless renin is added to the
perfusion buffer.3 Because renin in circulating blood
plasma is predominantly present in the form of its inactive
precursor, prorenin,4 it is also conceivable that kidney-
derived prorenin, after its local activation, contributes to
vascular angiotensin generation.
Renin and/or prorenin may enter the vascular wall through
binding to (pro)renin receptors. Indeed, we have recently
demonstrated that human umbilical vein endothelial cells
(HUVECs) bind renin and prorenin to cell surface mannose
6-phosphate (M6P) receptors.5 Binding was followed by
internalization and proteolytic activation of prorenin. The
latter process is not unique, inasmuch as M6P receptors are
known to be involved in the activation of several other
prohormones carrying the M6P recognition marker, such as
thyroglobulin.6 Moreover, M6P receptor–mediated prorenin
activation also occurs in cardiac cells.7 The enzyme respon-
sible for prorenin activation is currently not known. Possible
candidates include cathepsin B, glandular kallikreins, and
members of the prohormone convertase family.8–10 Further-
more, receptors other than the M6P receptor may also
contribute to (pro)renin binding.11,12
It was the aim of the present study to investigate the
kinetics of prorenin binding and activation in HUVECs, the
nature of the prorenin-activating enzyme in these cells,
endothelial prorenin binding independent of M6P receptors,
and whether endothelial prorenin binding and activation
result in angiotensin generation.
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Methods
Human Prorenin Preparations
Recombinant human prorenin (wild-type prorenin), produced in
Chinese hamster ovary cells transfected with a vector containing
human prorenin cDNA, was kindly provided by Dr S. Mathews
(Hoffmann-LaRoche, Basel, Switzerland).5 To remove traces of
renin, it was partially purified by Cibacron blue Sepharose affinity
chromatography (Pharmacia).5,7 Wild-type prorenin was stored at
280°C in aliquots containing ’23105 U/L (4 mmol/L) in 0.1%
BSA. It was also separated into an M6P-containing and an M6P-free
fraction by use of a bovine M6P receptor affinity column, provided
by Dr S. Kornfeld (Washington University School of Medicine, St.
Louis, Mo).13 In short, 1 U recombinant wild-type prorenin was
applied to a 0.5-mL bovine M6P receptor affinity column. The
column was washed with column buffer,13 and M6P-containing
prorenin was eluted by adding 10 mmol/L M6P to the column buffer.
Fractions corresponding to the column run-through material (ie,
M6P-free prorenin) and to M6P-eluted material (ie, M6P-containing
prorenin) were separately pooled and stored at 280°C in aliquots
containing ’100 U/L.
K/A-2 prorenin, ie, prorenin that cannot be cleaved by known
proteases, was produced in GH4 cells transfected with a vector
containing human prorenin cDNA in which Lys42 is mutated to
Ala.14 Nonglycosylated prorenin was produced in GH4 cells trans-
fected with a vector containing human prorenin cDNA in which Asn
at positions 5 and 75 of renin is mutated to Ser.15 The K/A-2 and
nonglycosylated prorenin mutants were stored at 280°C in aliquots
containing ’700 and 30 U/L, respectively, in DMEM with 5% FCS.
Cell Culture
HUVECs were isolated from umbilical cords, cultured to confluence,
trypsinized, and stored in liquid nitrogen as described earlier.5 For an
experiment, an aliquot of HUVECs (passages 2 to 5) was thawed.
The cells were cultured to confluence in a 75-cm2 tissue culture flask
coated with fibronectin (10 mg/cm2) in modified medium 199
containing 10% newborn calf serum, 10% human serum, 150 mg/mL
endothelial cell growth factor,5 15 U/mL heparin, 50 U/mL penicil-
lin, and 5 mg/mL streptomycin at 37°C in a humid 5% CO2
atmosphere. Cells were trypsinized and seeded in 12-well plates.
Studies were carried out ’1 day after confluence (corresponding to
a density of 43104 cells/cm2) had been reached. Before the start of
each experiment, the cells were washed 3 times with 2 mL warm
(37°C) PBS (140 mmol/L NaCl, 2.6 mmol/L KCl, 1.4 mmol/L
KH2PO4, and 8.1 mmol/L Na2HPO4, pH 7.4). The cells were then
preincubated either at 37°C or 4°C for 30 minutes with 0.5 mL
incubation medium consisting of modified medium 199 without
newborn calf serum or human serum but supplemented with 1%
human serum albumin.
Incubation With Prorenin at 4°C or 37°C
After preincubation at 37°C or 4°C for 30 minutes, experiments were
started by replacing the incubation medium by incubation medium of
37°C or 4°C containing wild-type prorenin (final concentration 3 to
300 U/L), M6P-containing wild-type prorenin (10 U/L), M6P-free
wild-type prorenin (10 U/L), K/A-2 prorenin (100 U/L), or nongly-
cosylated prorenin (10 U/L) with or without 10 mmol/L M6P. Cells
were then incubated at 37°C or 4°C for maximally 4 hours. To
investigate the nature of the prorenin-renin–converting enzyme,
incubations at 37°C with wild-type prorenin (100 U/L) were also
performed in the presence of the serine protease inhibitors 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF,
0.5 mmol/L, Calbiochem), aprotinin (0.001 mmol/L, Hoffmann-
LaRoche), and chymostatin (0.1 mmol/L, Hoffmann-LaRoche), the
cysteine protease inhibitor L-trans-3-carboxyoxiran-2-carbonyl-L-
leucylagmatine (E-64, 0.1 mmol/L, Sigma Chemical Co), the mixed
serine/cysteine protease inhibitor leupeptin (0.1 mmol/L, Sigma), the
metalloprotease inhibitors EDTA (1 mmol/L), phenanthroline
(1 mmol/L, Merck), and phosphoramidon (0.5 mmol/L, Sigma), and
the aspartic protease inhibitor pepstatin A (0.1 mmol/L, Sigma). At
the end of the incubation period, the culture medium was removed.
The cells were washed 3 times with 2 mL ice-cold PBS and lysed in
0.2 mL ice-cold PBS containing 0.2% Triton X-100. Subsequently,
the cell lysate was frozen on dry ice. Cell lysates were stored at
280°C.
To distinguish cell surface–bound from internalized prorenin, the
acid-wash method was used.7 Cells were then lysed as described
above.
Incubation With Prorenin at 4°C Followed by
Incubation at 37°C
The kinetics of prorenin internalization and activation were studied
by incubating HUVECs, which were cultured in 6-well plates, with
1 mL wild-type prorenin-containing incubation medium (final con-
centration 100 U/L) for 2 hours at 4°C. Thereafter, the cells were
washed 3 times with 3 mL ice-cold PBS and further incubated at
37°C with prorenin-free incubation medium. The incubation was
terminated after various times (ranging from 10 to 360 minutes) by
washing the cells 3 times with 3 mL ice-cold PBS. The cells were
then lysed in 0.5 mL ice-cold PBS containing 0.2% Triton X-100 as
described above. Cell lysates were stored at 280°C.
Angiotensin Generation During Incubation With
Prorenin at 37°C
To study prorenin-induced endothelial angiotensin generation,
HUVECs, which were cultured in 6-well plates, were incubated at
37°C for 4 hours with 1 mL incubation medium containing 10 U/L
wild-type prorenin and/or 150 nmol/L human angiotensinogen (Sig-
ma). HUVECs incubated without prorenin or angiotensinogen served
as the control. After 4 hours of incubation, the medium was rapidly
mixed with 50 mL inhibitor solution (containing 0.1 mmol/L
remikiren, 200 mmol/L disodium EDTA, and 0.2 mmol/L lisinopril)
and frozen at 270°C. Cells used for the measurement of angioten-
sinogen were washed 3 times with 3 mL ice-cold PBS and lysed in
0.2 mL ice-cold PBS containing 0.2% Triton X-100 as described
above. Cells used for the measurement of angiotensin I (Ang I) and
Ang II were scraped with a rubber policeman in a volume of 0.5 mL
ice-cold PBS. The cell-PBS mixture was centrifuged at 1000g at 4°C
for 1 minute, after which the pellet was homogenized in 0.5 mL 0.1
mol/L HCl/80% ethanol by using a hand-operated Dounce homog-
enizer. 125I-Ang I was added to the samples before the homogeniza-
tion procedure to determine angiotensin recovery. Ethanol was
evaporated under vacuum rotation at 4°C by using a Speed Vac
Concentrator. The concentrated homogenates were dissolved in 0.5
mL 1% orthophosphoric acid and applied to Sep-Pak columns (see
below).
In view of the partial catalytic activity of prorenin,16 Ang I was
also measured in incubation medium containing 10 U/L wild-type
prorenin and/or 150 nmol/L angiotensinogen that had been incubated
without HUVECs for 4 hours at 37°C.
Finally, HUVEC-mediated Ang I–Ang II conversion and Ang I
degradation was studied by incubating HUVECs for up to 4 hours at
37°C with 1 nmol/L Ang I in the presence or absence of 10 mmol/L
quinaprilat. Samples (0.1 mL) for the measurement of Ang I and II
were taken at 0, 0.5, 1, 2, and 4 hours, rapidly mixed with 10 mL
inhibitor solution, and frozen at 270°C.
Biochemical Measurements
Total prorenin (ie, cell-activated plus nonactivated) and cell-acti-
vated prorenin in the cell lysates obtained from the 37°C experiments
were measured by immunoradiometric assay (IRMA).17 Proteolytic
activation of prorenin in these experiments was verified with an
IRMA specific for intact prorenin, ie, prorenin in which the
C-terminal part of the prosegment is still attached to the renin part of
the molecule.5 The results of these IRMAs are expressed as mi-
crounits per 106 cells with intact recombinant human prorenin used
as a reference. The lower limit of detection was 5 mU/106 cells. The
IRMAs are not sensitive enough to measure the low levels of
prorenin that were present in the cell lysates at 4°C. Therefore, the
prorenin measurements in these experiments were performed by
enzyme-kinetic assay.7 The results of this assay are expressed as
microunits per 106 cells with plasmin-activated recombinant human
prorenin used as a reference. The lower limit of detection was 1
mU/106 cells.
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The concentration of angiotensinogen in the cell lysates was
determined as the maximum quantity of Ang I that was generated
during incubation at 37°C and pH 7.4 with excess recombinant
human renin in the presence of a mixture of angiotensinase, ACE,
and serine protease inhibitors.17–19 The lowest level that could be
measured was 20 fmol/106 cells.
Ang I and II levels in medium and in cell homogenates were
measured by radioimmunoassay after Sep-Pak extraction and
reversed-phase high-performance liquid chromatography separa-
tion.18,19 Recovery was better than 65%, and results were corrected
for incomplete recovery. The lower limits of detection for Ang I and
II were 2 and 1 fmol per milliliter medium or per 106 cells,
respectively.
Statistical Analysis
All data are expressed as mean6SEM. Differences between the
cellular prorenin levels at 37°C and 4°C and between the cellular
levels of total prorenin and cell-activated prorenin in the presence or
absence of protease inhibitors were evaluated for statistical signifi-
cance by ANOVA. Statistical significance was accepted at P,0.05.
Results
Incubation With Prorenin at 4°C or 37°C
HUVECs bound wild-type prorenin in a concentration-
dependent manner at 4°C and at 37°C (Figure 1). Cell-
associated prorenin at 37°C, but not at 4°C, was acid resistant
(data not shown), indicating that prorenin internalization
occurred at 37°C only. For a given prorenin concentration in
the medium, the level of cell-associated prorenin after 4 hours
of incubation was 10 times higher at 37°C than at 4°C.
Prorenin activation was detectable at 37°C only. Saturation of
the activation process did not occur, inasmuch as the percent-
age of cell-associated prorenin that was activated was similar
at all concentrations of prorenin to which the cells were
exposed (ranging from 8265% at 3 U/L to 7666% at 300
U/L, n56; P5NS). None of the protease inhibitors that were
tested (n55 for each inhibitor) blocked the activation of
prorenin (ranging from 6865% [with AEBSF] to 8169%
[with EDTA]), although some inhibitors affected the amount
of cell-associated total prorenin. E64, leupeptin, and pepstatin
A increased the levels of cell-associated total prorenin to
13569%, 138611%, and 12667% of control (P,0.05 ver-
sus control), respectively, thereby indicating that cysteine and
aspartic proteases contribute to (pro)renin degradation in
endothelial cells. AEBSF and phenanthroline reduced the
levels of cell-associated total prorenin to 4967% and 3967%
of control, respectively (P,0.05). This was not due to
interference with the internalization process, because the
percentage of cell-associated prorenin that was acid resistant
was similar in the presence and absence of these inhibitors
(data not shown). Aprotinin (9669% of control), chymostatin
(11966%), EDTA (8568%), and phosphoramidon (9469%)
did not affect the levels of cell-associated total prorenin.
K/A-2 prorenin was bound and internalized by HUVECs to
the same degree as wild-type prorenin (Figure 2, left).
Moreover, after 4 hours of incubation with K/A-2 prorenin at
37°C, 8062% of cell-associated total prorenin was in the
activated form. The activation was due to proteolytic cleav-
age of the prosegment, inasmuch as ,30% of cell-associated
total prorenin still contained the C-terminal part of the
prosegment. Furthermore, the rate of prorenin activation over
the 4-hour incubation period was identical for wild-type and
K/A-2 prorenin (Figure 2, right). Taken together, therefore,
HUVECs activated K/A-2 prorenin in a manner indistin-
guishable from the activation of wild-type prorenin, thereby
supporting the idea that activation was not mediated by any of
the known prorenin-renin convertases.
M6P significantly inhibited native prorenin binding at
37°C and at 4°C (Figure 3). In the presence of M6P, prorenin
binding was observed only at prorenin concentrations .10
U/L, and the levels of cell-associated prorenin were identical
at 37°C and at 4°C. Scatchard analysis of the results obtained
at 4°C revealed that M6P receptor–specific binding of prore-
nin occurred with high affinity (Kd 0.960.1 nmol/L). The
number of prorenin-binding M6P receptors on the cell surface
(Bmax) was 1010650 sites per cell.
Binding studies after the separation of wild-type prorenin
into an M6P-free and an M6P-containing fraction, with the
help of a bovine M6P receptor affinity column, revealed that
only M6P-containing prorenin and not M6P-free prorenin
was bound by HUVECs (Figure 4). In agreement with this
finding, the cells did not bind or internalize nonglycosylated
prorenin (n54, data not shown).
Figure 1. Cell-associated prorenin after incubation of HUVECs
with wild-type prorenin at 4°C (left) or 37°C (right) for 4 hours.
The open and closed circles represent the cellular levels of cell-
activated and total (cell-activated plus nonactivated) prorenin,
respectively. Data are mean6SEM (n56).
Figure 2. Left, Cellular levels of cell-activated (open bars) and
intact prosegment-containing (closed bars) prorenin after incu-
bation of HUVECs for 4 hours at 37°C with wild-type or K/A-2
prorenin. Levels (mean6SEM, n54) are expressed as a percent-
age of the cellular levels of total (cell-activated plus nonacti-
vated) prorenin after 4 hours of incubation. Right, Time-
dependent increase in the cellular levels of activated prorenin
during incubation of HUVECs at 37°C with wild-type prorenin
(open circles) or K/A-2 prorenin (closed circles). Levels
(mean6SEM, n54) are expressed as a percentage of the cellu-
lar levels of total prorenin after 4 hours of incubation.
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Incubation With Prorenin at 4°C Followed by
Incubation at 37°C
After 2 hours of incubation at 4°C with 100 U/L wild-type
prorenin, followed by repeated washing with ice-cold PBS,
the level of cell-associated total prorenin was 197626
mU/106 cells (n55). Acid wash confirmed that all cell-
associated prorenin at that time was located on the cell
surface. Immediately after elevating the temperature to 37°C,
the level of cell-associated total prorenin started to decrease.
The decrease followed a biphasic pattern (Figure 5). The
rapid phase (half-time [t1/2] 761 minutes) corresponds with
the release of cell-associated prorenin into the medium,
whereas the slow phase (t1/2 405672 minutes) represents
intracellular degradation after internalization. As soon as
prorenin release into the medium no longer occurred (ie, at
the time all remaining cell surface–bound prorenin had been
internalized, after ’40 minutes), the cellular levels of acti-
vated prorenin started to rise rapidly, reaching a maximum
after 60 minutes. Thereafter, these levels decreased with a
half-life (t1/2 305633 minutes) similar to that of the degra-
dation of cell-associated total prorenin. Taken together, these
findings suggest that activation precedes degradation and that
the half-lives of both processes differ 40- to 60-fold.
Angiotensin Generation During Incubation With
Prorenin at 37°C
HUVECs that had been incubated under serum-free condi-
tions for 4 hours in the absence of prorenin and angioten-
sinogen did not contain detectable levels of angiotensinogen,
Ang I, or Ang II (n54), nor could these renin-angiotensin
system components be demonstrated in the medium (n54) of
these cells. Cellular angiotensinogen and angiotensin levels
remained undetectable after a 4-hour incubation with 10 U/L
wild-type prorenin and/or 150 nmol/L angiotensinogen (n54
for each condition). Medium of HUVECs that had been
incubated for 4 hours with 10 U/L wild-type prorenin plus
150 nmol/L angiotensinogen contained 569685 pmol/L Ang
I and 125626 pmol/L Ang II (n54). A 4-hour incubation of
medium containing the same amount of wild-type prorenin
and angiotensinogen in the absence of HUVECs also resulted
in the appearance of Ang I (25206130 pmol/L, n54) but not
Ang II. Medium containing either prorenin or angioten-
sinogen, after incubation with or without HUVECs, did not
contain angiotensins (n54 for each condition).
HUVECs metabolized Ang I (t1/2 1.060.1 hour, n54),
and this resulted in the appearance of Ang II in the medium,
which reached a peak level (191624 pmol/L) after 2 hours.
Quinaprilat fully prevented the generation of Ang II. On the
basis of the half-life of Ang I in the presence of the ACE
inhibitor (t1/2 1.760.2 hours, n54; P,0.01 versus control),
Figure 3. Cell-associated prorenin after incubation of HUVECs
with wild-type prorenin in the absence (closed circles) or pres-
ence (closed squares) of 10 mmol/L M6P at 4°C (left) or 37°C
(right) for 4 hours. M6P receptor–specific binding (open trian-
gles) was taken as the difference between levels of cell-
associated prorenin with and without M6P. Data are
mean6SEM (n56). B/F indicates bound-to-free ratio; B, bound
prorenin. Kd and Bmax were calculated from a plot according to
Scatchard (insert).
Figure 4. Cell-associated prorenin after incubation of HUVECs
with nonfractionated wild-type prorenin (10 U/L), M6P-
containing wild-type prorenin (10 U/L), and M6P-free wild-type
prorenin (10 U/L) at 4°C (top) or 37°C (bottom) for 4 hours in the
absence (open bars) or presence (closed bars) of 10 mmol/L
M6P. Data (mean6SEM, n55) are expressed as a percentage of
the cellular levels of control (1669 mU/106 cells and 158651
mU/106 cells at 4°C and 37°C, respectively).
Figure 5. Time course of internalization and cellular activation of
wild-type prorenin by HUVECs. Cells were preincubated with
prorenin (100 U/L) for 2 hours at 4°C. They were then washed
with ice-cold PBS, fresh culture medium free of prorenin was
added, and the incubation was continued at 37°C. The cellular
level of total prorenin (cell-activated plus nonactivated) at the
end of the preincubation at 4°C (0 minutes) was 197626 mU/106
cells (100%). The open and closed circles represent the cellular
levels of cell-activated and total prorenin, respectively. Data are
mean6SEM (n55).
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calculations19 revealed that 4267% of the Ang I metabolism
by HUVECs was due to conversion by ACE.
Discussion
With the use of prorenin mutants as well as wild-type
prorenin, the present study shows that endothelial internal-
ization and activation of prorenin are mediated exclusively
via M6P receptors. We have demonstrated earlier that these
receptors also bind and internalize renin, in a manner indis-
tinguishable from that of prorenin.5 Thus, despite evidence of
the presence of other M6P-independent (pro)renin receptors
in vascular preparations,11 our data do not support the idea
that such receptors are localized on human endothelial cells.
M6P receptor–dependent (pro)renin binding to endothelial
cells also provides an explanation for the selective endothelial
staining of renin in human arteries.20
At present, 2 different M6P receptors have been identified:
the cation-independent type (also known as insulin-like
growth factor II [IGFII] receptor) and the cation-dependent
type. These receptors contain 2 M6P binding sites and 1 M6P
binding site, respectively.21 The high-affinity binding of
prorenin in the present study resembles the high-affinity
binding of diphosphorylated oligosaccharides that occupy 2
M6P binding sites.22 Most likely, therefore, the endothelial
prorenin-binding receptor is the cation-independent M6P
receptor. In this respect, prorenin resembles other M6P-
carrying prohormones that are internalized and activated after
binding to cell surface cation-independent M6P receptors.6
Internalized prorenin was rapidly activated to renin, and
the activation occurred proteolytically, as evidenced by the
use of an antibody directed against the C-terminal part of the
prosegment. Inhibitors of known proteases did not prevent
cleavage, although some inhibitors interfered with the subse-
quent renin degradation by cysteine and aspartic proteases.
The latter shows that protease inhibitors do enter endothelial
cells and thus confirms that their lack of effect on prorenin
activation is not due to their inability to get into the cells.
Unexpectedly, K/A-2 prorenin, a prorenin mutant that is not
cleaved in vitro in isolated cells or in vivo in rat pituitary
glands,10,14,23 was also cleaved to renin. Remarkably, its
activation occurred as rapidly as that of wild-type prorenin,
although in vitro we found that plasmin activated K/A-2
prorenin 4 to 5 times as slowly as it did wild-type prorenin
(authors’ unpublished data, 2000). Taken together, therefore,
endothelial cells contain an as-yet-unidentified protease that
is capable of cleaving prorenin at or near its natural cleavage
site. The rapidity of this process after internalization suggests
that this enzyme is located in endosomes.
Activated intracellular prorenin may contribute to endothe-
lial angiotensin generation. This would require the simulta-
neous uptake or endothelial synthesis of angiotensinogen.
The demonstration of Ang II in the cytoplasm of rat endo-
thelial cells24 and of the release of intracellularly generated
Ang II from bovine endothelial cells25 supports this concept.
However, we were unable to demonstrate intracellular endo-
thelial angiotensin generation during the incubation of
HUVECs with prorenin and angiotensinogen. Although Ang
I and II could be detected in the medium during these
experiments, it is important to note that Ang I generation also
occurred during the incubation of prorenin and angioten-
sinogen in the absence of HUVECs and that the addition of
Ang I to HUVECs resulted in the immediate appearance of
Ang II in the medium. Taken together, therefore, the presence
of Ang I and II in the medium of cells incubated with prorenin
and angiotensinogen most likely reflects the partial catalytic
activity of prorenin that is due to the temporal unfolding of its
prosegment16 rather than endothelial activation of prorenin.
On the basis of the Ang I level measured after 4 hours of
prorenin plus angiotensinogen incubation in the absence of
HUVECs, it can be estimated that ,2% of prorenin is
catalytically active; ie, it exists in an “open” form.
The absence of intracellular angiotensin generation, despite
the prorenin internalization (and subsequent activation) that
occurred at 37°C, is most likely due to the fact that HUVECs
did not sequester angiotensinogen. Although this does not
necessarily apply to all endothelial cells in the human body,
it suggests that intraendothelial angiotensin generation will
occur only in endothelial cells that synthesize angioten-
sinogen. Evidence for the latter is currently not available.
In the absence of intracellular angiotensin generation, the
high vascular levels of Ang II26 can be explained only on the
basis of AT1 receptor–mediated internalization of Ang II after
its extracellular generation.27,28 Such extracellular angioten-
sin generation most likely involves interstitial renin29 or renin
bound to the surface of vascular cells via receptors other than
the M6P receptor.11,12,30
Finally, in view of the intracellular degradation of activated
prorenin, it is conceivable that M6P receptors function as
clearance receptors of (pro)renin and that prosegment cleav-
age is a first step toward intracellular destruction. For
instance, binding and internalization of IGFII to M6P/IGFII
receptors results in the lysosomal degradation of this ligand.6
An argument against this concept is the large difference in
half-life between prorenin activation and degradation. This
difference would leave activated prorenin ample time to
contribute to intracellular angiotensin generation. However,
even if M6P receptors serve as clearance receptors for
(pro)renin, this would still allow these receptors to affect
vascular angiotensin generation.
In conclusion, prorenin internalization by HUVECs is
mediated exclusively via high-affinity M6P receptors and is
greatly enhanced by receptor recycling. Internalized prorenin
is rapidly activated to renin by a protease that is different
from any of the known prorenin-activating enzymes. Activa-
tion is followed by degradation and/or, if angiotensinogen is
present, may result in intracellular angiotensin generation.
Both possibilities support the regulation of vascular angio-
tensin generation by M6P receptors.
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